• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, August 28, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Alzheimer’s therapy may help overcome opioid addiction

Bioengineer by Bioengineer
June 5, 2019
in Health
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Clinical trial results reveal that a medication used to treat Alzheimer’s disease may also be an effective therapy for individuals addicted to opioids. The findings are published in The American Journal on Addictions.

The medication, called galantamine, is thought to have a dual mechanism of action–it increases levels of a chemical messenger called acetylcholine in the brain and also binds to nicotinic receptors, which play a role in addiction to nicotine and other substances.

Participants who took galantamine had fewer urine samples that were positive for opioids compared with those who took placebo, which corroborated with self-reported abstinence in those who took galantamine. Also, participants who used opioids during follow-up took longer to do so if they were in the galantamine group.

“My colleagues and I are excited about these preliminary findings, as they could point to new strategies for helping those with opioid use disorder. We hope to pursue this in future research,” said lead author Kathleen Carroll, PhD, of the Yale University School of Medicine.

###

Media Contact
Penny Smith
[email protected]
http://dx.doi.org/10.1111/ajad.12904

Tags: AddictionDrugsMedicine/HealthPublic Health
Share13Tweet8Share2ShareShareShare2

Related Posts

Borosilicate Glass Enhances Magnetic Hyperthermia Against Bone Tumors

August 28, 2025

Gastrointestinal Effects of Incretin Obesity Drugs Explored

August 28, 2025

Zharp1-163: Dual Inhibitor Tackles Inflammation, Kidney Injury

August 28, 2025

Enhancing Pediatric Nursing Education with Advanced Simulators

August 28, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    82 shares
    Share 33 Tweet 21

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Borosilicate Glass Enhances Magnetic Hyperthermia Against Bone Tumors

Penn Engineers Transmit Quantum Signals Using Standard Internet Protocol

Gastrointestinal Effects of Incretin Obesity Drugs Explored

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.